Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Angiodynamics (ANGO) EBITDA (2016 - 2026)

Angiodynamics' EBITDA history spans 17 years, with the latest figure at -$13.0 million for Q1 2026.

  • For Q1 2026, EBITDA fell 29.85% year-over-year to -$13.0 million; the TTM value through Feb 2026 reached -$35.5 million, up 26.94%, while the annual FY2025 figure was -$40.0 million, 79.24% up from the prior year.
  • EBITDA reached -$13.0 million in Q1 2026 per ANGO's latest filing, down from -$6.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $35.0 million in Q3 2023 to a low of -$199.9 million in Q1 2024.
  • Average EBITDA over 5 years is -$19.1 million, with a median of -$10.7 million recorded in 2025.
  • Peak YoY movement for EBITDA: soared 363.36% in 2023, then crashed 2138.98% in 2024.
  • A 5-year view of EBITDA shows it stood at -$8.1 million in 2022, then crashed by 61.68% to -$13.1 million in 2023, then rose by 15.44% to -$11.1 million in 2024, then skyrocketed by 44.79% to -$6.1 million in 2025, then plummeted by 111.44% to -$13.0 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's EBITDA are -$13.0 million (Q1 2026), -$6.1 million (Q4 2025), and -$10.7 million (Q3 2025).